Galectin-3 plasma levels and coronary artery disease: A new possible biomarker of acute coronary syndrome

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 4, 2011, Pages 905-913

  Falcone, Colombo ^a,b   Lucibello, S ^a   Mazzucchelli, I ^a   Bozzini, S ^a   D'Angelo, A ^a   Schirinzi, S ^a   Totaro, R ^a   Falcone, R ^a   Bondesan, M ^a   Pelissero, G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

CAD; Galectin 3; Stable and unstable angina

Indexed keywords

BIOLOGICAL MARKER; GALECTIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; C REACTIVE PROTEIN; CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STENOSIS; AGE DISTRIBUTION; BLOOD VESSEL; DISEASE ASSOCIATION; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; MEDICAL EXAMINATION; MONOCYTE; OBSERVATIONAL STUDY; RISK ASSESSMENT; RISK FACTOR; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

EID: 84856581939     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400409     Document Type: Article

References (29)

1. Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54:2129-38.
2. Uno K, Nicholls SJ. Biomarkers of inflammation and oxidative stress in atherosclerosis. Biomark Med 2010; 4:361-73.
3. Drakopoulou M, Toutouzas K, Stefanadi E, Tsiamis E, Tousoulis D, Stefanadis C. Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis 2009; 206:335-9.
4. Sano H, Hsu DK, Apgar JR, Yu L, Sharma BB, Kuwabara I, Izui S, Liu FT. Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest 2003; 112:389-97. (Pubitemid 38063767)
5. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002; 1572:263-73. (Pubitemid 35246349)
6. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J 2004; 19:527-35. (Pubitemid 38316526)
7. Nachtigal M, Al-Assaad Z, Mayer EP, Kim K, Monsigny M. Galectin-3 expression in human atherosclerotic lesions. Am J Pathol 1998; 152:1199-208. (Pubitemid 28221873)
8. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008; 28:433-40.
9. Liu YH, D'Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, André S, Gabius HJ, Carretero OA. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009; 296:H404-12.
10. Nieminen J, St-Pierre C, Sato S. Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses. J Leukoc Biol 2005; 78(5):1127-35. Erratum in: J Leukoc Biol 2008; 83:797. (Pubitemid 41572476)
11. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009; 230:160-71.
12. De Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Cur Heart Fail Rep 2010; 7:1-8.
13. Christenson RH, Duh SH, Wu AH, et al. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem 2010; 43:683-90.
14. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110:3121-28. (Pubitemid 39492008)
15. De Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43:60-68.
16. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011; 108:385-90.
17. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760:616-35.
18. Al-Ansari S, Zeebregts CJ, Slart RH, Peppelenbosch M, Tio RA. Galectins in atherosclerotic disease. Trends Cardiovasc Med 2009; 19:164-9.
19. Arar C, Gaudin JC, Capron L, Legrand A. Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett 1998; 430:307-11. (Pubitemid 28337934)
20. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 2008; 172:247-55. (Pubitemid 351186385)
21. Mensah-Brown EP, Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic N, Hsu DK, Liu FT, Lukic ML. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin Immunol 2009; 130:83-88.
22. MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008; 180:2650-8.
23. Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, Hirashima M, Liu FT. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000; 165:2156-64. (Pubitemid 30643165)
24. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995; 1:634-46.
25. Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun 2001; 280:1183-88. (Pubitemid 32924465)
26. Frol'ová L, Smetana K Jr, Borovská D, et al. Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD? Inflamm Res 2009; 58:503-12.
27. Forsman H, Islander U, Andréasson E, et al. Galectin-3 aggravates joint inflammation and destruction in antigen-induced arthritis. Arthritis Rheum 2010.
28. Kang EH, Moon KC, Lee EY, Lee YJ, Lee EB, Ahn C, Song YW. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus 2009; 18:22-8.
29. Vereecken P, Heenen M. Serum galectin-3 in advanced melanoma patients: a hypothesis on a possible role in melanoma progression and inflammation. J Int Med Res 2006; 34:119-20.